Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments

  • Technology appraisal guidance
  • TA862
  • Published: 

Tools and resources

Education

Resource impact

Guidance into practice